Researchers have studied human kidney cells in the lab to look at the effects of COVID-19 on kidney well being. The findings seem in an upcoming subject of JASN.
Many people who develop COVID-19 additionally expertise kidney injury, however it’s unclear if this can be a direct outcome of viral an infection or a consequence of one other situation or the physique’s response to the an infection. To examine, a staff led by Benjamin Dekel, MD, PhD (Sheba Medical Center, in Israel) cultivated human kidney cells in lab dishes and contaminated them with the virus that causes COVID-19.
The researchers discovered that though the virus that causes COVID-19 may enter, infect, and replicate in human grownup kidney cells, this didn’t usually result in cell loss of life. Prior to an infection, the cells contained excessive ranges of interferon signaling molecules, and the an infection stimulated an inflammatory response that elevated these molecules. In distinction, an infection of kidney cells poor in such molecules resulted in cell loss of life, suggesting a protecting impact.
The cells in these experiments have been grown as a three-dimensional spheroid that imitates the wholesome kidney or as a two-dimensional layer that mimics the cells of an acutely injured kidney. Cells that mimicked an acutely injured kidney have been extra liable to an infection and extra damage however not cell loss of life.
“The data indicate that it is unlikely that the virus is a primary cause of acute kidney injury seen in COVID-19 patients. It implies that if such injury takes place in the kidney by any cause, the virus might jump on the wagon to intensify it. Therefore, if we’re able to limit the common scenario of acute kidney injury in the first place, then there might be the possibility to minimize potential damage caused by the virus,” Dr. Dekel defined.
Study co-authors from the Sheba Medical Center and the Israel Institute for Biological Research embrace Dorit Omer, PhD, Oren Pleniceanu, MD, PhD, Yehudit Gnatek, MSc, Michael Namestnikov, Osnat Cohen-Zontag, PhD, Sanja Goldberg, PhD, Yehudit Eden Friedman, MD, Nehemya Friedman, PhD, Michal Mandelboim, PhD, Einat B. Vitner, PhD, Hagit Achdout, PhD, Roy Avraham, PhD, Eran Zahavy, PhD, Tomer Israely, PhD, and Haim Mayan, MD.
Disclosures: Dr. Dekel is a co-founder and shareholder at KidneyCure Ltd.
Materials supplied by American Society of Nephrology. Note: Content could also be edited for fashion and size.